Previous Article | Next Article 
Journal of Clinical Microbiology, July 2001, p. 2531-2540, Vol. 39, No. 7
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.7.2531-2540.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Identification of Rifampin-Resistant Mycobacterium
tuberculosis Strains by Hybridization, PCR, and Ligase
Detection Reaction on Oligonucleotide Microchips
Vladimir
Mikhailovich,1
Sergey
Lapa,1
Dimitry
Gryadunov,1
Alexander
Sobolev,1
Boris
Strizhkov,1
Nikolai
Chernyh,1
Olga
Skotnikova,2
Olga
Irtuganova,2
Arkadii
Moroz,2
Vitalii
Litvinov,2
Mikhail
Vladimirskii,3
Mikhail
Perelman,3
Larisa
Chernousova,4
Vladislav
Erokhin,4
Alexander
Zasedatelev,1 and
Andrei
Mirzabekov1,5,*
Biochip Technology Center, Argonne National
Laboratory, Argonne, Illinois,5 and
Moscow Anti-Tuberculosis Center, Moscow
Government,2 Research Institute for
Phthisiopulmonology, I. M. Sechenov Moscow Medical
Academy,3 Engelhardt Institute of
Molecular Biology,1 and Central TB
Research Institute, Russian Academy of Medical
Sciences,4 Moscow, Russia
Received 22 December 2000/Returned for modification 21 February
2001/Accepted 21 April 2001
 |
ABSTRACT |
Three new molecular approaches were developed to identify
drug-resistant strains of Mycobacterium tuberculosis
using biochips with oligonucleotides immobilized in polyacrylamide gel
pads. These approaches are significantly faster than traditional
bacteriological methods. All three approaches
hybridization, PCR,
and ligase detection reaction
were designed to analyze an 81-bp
fragment of the gene rpoB encoding the
-subunit of
RNA polymerase, where most known mutations of rifampin resistance are
located. The call set for hybridization analysis consisted of 42 immobilized oligonucleotides and enabled us to identify 30 mutant
variants of the rpoB gene within 24 h. These
variants are found in 95% of all mutants whose rifampin resistance is
caused by mutations in the 81-bp fragment. Using the second approach,
allele-specific on-chip PCR, it was possible to directly identify
mutations in clinical samples within 1.5 h. The third approach,
on-chip ligase detection reaction, was sensitive enough to reveal
rifampin-resistant strains in a model mixture containing 1% of
resistant and 99% of susceptible bacteria. This level of sensitivity
is comparable to that from the determination of M.
tuberculosis drug resistance by using standard
bacteriological tests.
 |
INTRODUCTION |
Tuberculosis (TB), one of the
most deadly and common infectious diseases, claims 3,000,000 lives a
year worldwide (24). Although the disease is found mostly
in developing countries, a growing number of cases are diagnosed in the
industrialized world as well. The global spread of the disease is
further complicated by the ubiquitous appearance of drug-resistant
(6) and especially multidrug-resistant strains that, by
definition, are resistant to at least rifampin (RIF) and isoniazid.
Thus, in 1996 13% of all newly diagnosed cases of TB in the United
States were resistant (primary resistance) to at least one first-line
drug and 1.6% were multidrug resistant (19).
After radical political changes in the former Soviet Union, the
incidence of TB and related mortality in Russia increased to levels
that are among the highest in the world. The incidence of TB in Russia
in the period between 1991 and 1997 increased from 34 to 82 per 100,000 adults (10), four to seven times higher than that in most
European countries. In view of the potential global spread of
multidrug-resistant forms of TB, special concerns arise regarding the
Russian penitentiary system. Its population presently exceeds
1,000,000, and 10% of the prisoners have active TB (for a review, see
reference 10). Among the prisoners, about 25% of all new
cases and 92% of nonresponding cases are drug resistant (7); according to another report, 66% of all cases are
drug resistant, 50% of which are RIF-resistant
(Rifr) forms (29).
According to the recommendations of the Centers for Disease Control and
Prevention, bacteriological laboratories must determine the resistance
of all submitted samples of M. tuberculosis to all
first-line antibiotics. This has to be done using the fastest methods
available, and final results must be reported within 30 days after
receiving the sample (32). Most laboratories incubate solid medium cultures for 8 weeks to achieve a better sensitivity (9). Several liquid-culture-based strategies, such
as MB/BacT (Organon-Teknika), MGIT, BACTEC 460TB, and BACTEC 9000 MB (Becton Dickinson), have been developed that allow the mean time
required for detection of Mycobacterium tuberculosis to be
reduced to 8 to 18 days (1, 3, 22). Subsequent assessment
of drug resistance may take another 3 weeks. Even with the most
advanced methods the turnaround times are 3 to 15 days for the BACTEC
460TB system (23, 27), 5 to 11 days for the MB/BacT system
(5), and 3 to 14 days for MGIT (26).
Therefore, there is an urgent need to develop simple, fast, and
cost-effective methods to identify drug resistance in mycobacteria that
could be used for large-scale population screening, particularly for
the screening of prisoners.
We focused our efforts on the resistance of M. tuberculosis
to RIF, probably the most efficient anti-TB drug and a key component of
modern chemotherapeutic cocktails of three to four drugs. RIF resistance could be considered a surrogate marker for
multidrug-resistant TB strains (31) and should therefore
be subject to the most rapid test performed.
The resistance of M. tuberculosis to RIF is caused by a
number of mutations. About 95% of these mutations are confined to a
short 81-bp-long DNA region in the gene rpoB encoding the
-subunit of RNA polymerase B, the so-called
RIF-resistance-determining region (RRDR) (20, 31). A
number of protocols have been developed to analyze the underlying
sequence polymorphisms of RRDR, including direct sequencing
(16), dideoxy fingerprinting (11),
PCR-heteroduplex analysis (36), single-strand conformation
polymorphism (28, 31), DNA probe arrays (13,
34), hybridization of PCR-amplified products to a limited set of
probes (8, 15, 25, 35), and RNA mismatch analysis
(21).
In the first approach we propose to use hybridization on an
oligonucleotide microarray
MAGIChips (38)
to identify
Rifr strains of M. tuberculosis in clinical samples within 24 h. This method is
based on the difference in stability between perfect and imperfect
duplexes formed by the fluorescently labeled target DNA and the probes
immobilized in gel pads of the dedicated TB biochip. The relative
intensities of fluorescence of the pads indicate the presence and the
nature of the mutations.
The second approach involves PCR amplification on MAGIChips. Using this
method, the time to identify Rifr strains
is further shortened to 1.5 h. In addition, it does not require
any special probe preparation and can be applied to simultaneous analysis of several variable segments of the bacterial genome.
Early detection of low-copy-number mutant DNA against a high background
of wild-type DNA is an important practical goal that requires high
sensitivity. The third approach, ligase detection reaction (LDR), is
applied to identify about 1% of mutant sequences in model samples
consisting of mixtures of DNA from wild-type and resistant strains.
 |
MATERIALS AND METHODS |
Oligonucleotides.
Oligonucleotides for hybridization
analysis and on-chip PCR were designed using the programs Oligo 5 (Molecular Biology Insights, Cascade, Colo.) and Primer
Calculator. The procedure included the following steps. First,
melting temperatures for perfect matches were determined for
prospective oligonucleotides. Second, the length of the
oligonucleotides was adjusted to maintain the range of melting
temperatures within 3 to 4°C for hybridization probes and 2 to 3°C
for PCR primers.
Oligonucleotides were synthesized on an ABI-394 DNA/RNA synthesizer
(Applied Biosystems, Foster City, Calif.) using standard phosphoramidite chemistry. Oligonucleotides were purified by
reverse-phase high-performance liquid chromatography on
C18-Nucleosil columns (Sigma, St. Louis, Mo.) for
hybridization and on-chip PCR and in denaturing polyacrylamide gel
electrophoresis for on-chip LDR. To immobilize oligonucleotides in gel
pads or to attach the fluorescent label Texas Red (Molecular Probes,
Inc., Eugene, Oreg.), an amino group was introduced during synthesis
using 3'-Amino-Modifier C7 CPG 500 or 5'-Amino-Modifier C6 (Glen
Research, Sterling, Va.). The attachment of the fluorescent group to
the amino group in oligonucleotides was carried out according to the
manufacturer's instructions. Interrogating oligonucleotides were
immobilized through their 3' ends; oligonucleotide primers were
immobilized or fluorescently labeled at their 5' ends; fluorescent
oligonucleotides that imitated target DNA with rare mutations were
labeled at their 3' ends.
M. tuberculosis strains.
M.
tuberculosis strains were isolated from sputum, pleural exudate,
bronchial lavage, urine, and cerebrospinal fluid of patients in central
Russia (Moscow City and Moscow and Kaluga regions), in the Siberian
regions of Russia (Novosibirsk and Tomsk), and in St. Petersburg,
Russia. All cultures were grown on Löwenstein-Jensen (LJ) agar
slants at 37°C for 8 weeks and were examined for growth rate, gross
and microscopic colony morphology, and pigmentation and also were
tested for niacin accumulation, nitrate reduction, and catalase and
urease activity (18). All cultures underwent standard
tests for RIF resistance using the absolute concentration method
(14) as follows. The cultures were grown on LJ agar
slants, and then the cells were resuspended in sterile saline (0.85%
NaCl) to turbidity corresponding to a cell density of 5 × 108 cells per ml. The suspension was further
diluted 10-fold with sterile saline, and a 0.2-ml aliquot was plated on
LJ solid medium (control) and on the same medium containing 40 µg of
RIF/ml. The samples that developed fewer than 20 colonies on
RIF-containing medium and showed normal growth on control medium by the
end of 4 weeks were considered RIF susceptible.
Preparation of DNA samples from M. tuberculosis
cultures.
One or two colonies of M. tuberculosis, 2 to
3 mm in diameter, were resuspended in 0.5 ml of TE buffer (10 mM
Tris-HCl, 1 mM EDTA [pH 8.0]) and centrifuged at 12,000 × g for 10 min at 4°C. The pellet was resuspended in 30 µl
of TE buffer containing 1% Triton X-100 and incubated for 20 min at
95°C. The extracts were cooled on ice and centrifuged at 12,000 × g for 10 min, and 2-µl aliquots of clear supernatant
were used for PCR.
Preparation of DNA samples from clinical specimens.
Specimens of sputum, pleural exudate, and bronchial lavage
(approximately 10 ml each) were decontaminated by treatment with N-acetylcysteine and 3% NaOH (17) for 40 min
at room temperature. Cell extracts were then obtained by centrifugation
and lysis as described above. Other bodily fluids (1.5 ml of urine or
0.5 ml of cerebrospinal fluid) were centrifuged at 10,000 × g for 10 min at 4°C. Cell extracts were prepared similarly
to the procedure used for pure bacterial culture as described above.
Two-microliter aliquots of clear supernatants were used for PCR.
Preparation of target DNA.
Target samples of DNA from
M. tuberculosis were prepared by two-stage PCR. At the first
stage, a 193-bp-long fragment of the rpoB gene (nucleotides
2288 to 2480; GenBank accession no. L27989) was amplified using primers
F105 (5'-CGT GGA GGC GAT CAC ACC GCA GAC GTT G-3') and R273
(5'-GAC CTC CAG CCC GGC ACG CTC ACG T-3'). The reaction
mixture contained 1.5 mM MgCl2, 10 mM KCl, 10 mM Tris-HCl (pH 8.3), 2.5 U of AmpliTaq DNA polymerase (PE Corporation, Norwalk, Conn.), 0.5 U of uracyl-DNA-glycosylase (Medigen,
Moscow, Russia), 100 nM concentrations of each primer, 2 µl of
DNA sample, and 0.2 mM (each) dATP, dCTP, dGTP, and dUTP. The reaction
was carried out in a MiniCycler (MJ Research, Waltham, Mass.) as
follows: 10 min at room temperature; 5 min at 95°C; 30 cycles of
30 s at 95°C and 40 s at 72°C; and 5 min at 72°C. Two
microliters of the reaction mixture obtained after the first reaction
was used for the second PCR.
In the second reaction, an internal 126-bp-long fragment (nucleotides
2336 to 2461 of the rpoB gene) of the first product was
amplified using primers F1272 (5'-CGC CGC GAT CAA GGA GTT CT-3') and R1398 (5'-TCA CGT GAC AGA CCG CCG GG-3').
The reaction mixture contained dTTP instead of the dUTP used in the
first reaction mixture, no uracyl-DNA-glycosylase, a 100 nM
concentration of fluorescently labeled F1272, and a 10 nM concentration
of R1398 in 100 µl. Because of the difference in the concentrations
of primers, the reaction yielded predominantly single-stranded
DNA. Amplification was carried out as follows: 5 min at
95°C; 35 cycles of 20 s at 95°C, 30 s at 65°C, and
30 s at 72°C; and 5 min at 72°C.
For on-chip LDR, predominantly single-stranded lower-strand (antisense)
DNA was amplified in a similar reaction. The F1272 primer was not
labeled and was used at 10 nM, while R1398 was used at 100 nM.
DNA-polymerase was removed by adding 1 µg of proteinase K (Sigma)/ml.
The mixture was incubated for 15 min at 37°C, 10 min at 55°C, and
then 10 to 15 min at 95°C to inactivate the proteinase.
PCR products were analyzed by electrophoresis in agarose gels.
Sequencing.
The fragment of the rpoB gene that
determines RIF resistance was amplified with primers F105 and R273 and
subjected to automated dideoxy sequencing using one of the terminal
primers, a commercial kit (Dye Deoxy Terminator ABI Sequencing Kit with
Taq-Polymerase FS; PE Corporation), and an ABI-373A
automatic sequencer (Applied Biosystems).
TB-MAGIChip with immobilized oligonucleotides.
The MAGIChips
were prepared as described earlier (38). Each chip
consisted of a microscope slide with 169 (13 by 13) polyacrylamide gel
pads created on its surface by photopolymerization. Each gel pad is a
100- by 100- by 20-µm block separated from adjacent blocks by a
200-µm-wide strip of hydrophobic surface. Each pad contained 1 pmol of an immobilized oligonucleotide probe. For hybridization, oligonucleotides were immobilized through their 3' ends; for on-chip PCR and LDR they were immobilized through their 5' ends.
On-chip hybridization.
A hybridization mixture was prepared
by adding 12 µl of the second-stage asymmetric PCR mixture to 24 µl
of a solution containing 1.5 M guanidine thiocyanate (GuCNS), 0.075 M
HEPES (pH 7.5), and 7.5 mM EDTA (unless noted otherwise). Twenty-eight
microliters of the hybridization mixture was loaded on the chip and
sealed in a hybridization chamber (10 by 10 mm) (in situ frame;
Eppendorf Scientific, Westbury, N.Y.). The chamber was incubated for
18 h at 37°C. After hybridization the chip was washed three
times at 37°C with 6.67× SSPE buffer, pH 7.4, containing 10% Tween
20, and was air dried.
On-chip PCR.
On-chip PCR was described earlier
(30). The reaction mixture contained 2.5 mM
MgCl2, 10 mM KCl, 10 mM Tris-HCl (pH 8.3), 1 mg
of bovine serum albumin/ml, 0.2 mM concentrations of each deoxynucleoside triphosphate, 5 U of the Stoffel fragment of
Taq DNA-polymerase (PE Corporation), a 33 nM concentration
of unlabeled forward primer (5'-CGC GAT CAA GGA GTT CTT CGG CAC
C-3'), and a 330 nM concentration of fluorescently labeled
reverse primer (5'-CCC GGC GGT CTG TAC GTG A-3'). This pair
of primers amplified a 133-bp-long fragment of the rpoB gene
(nucleotides 2339 to 2471). PCR was carried out as follows: 2 min at
95°C and 25 to 35 cycles of 30 s at 95°C, 60 s at 63°C,
and 40 s at 72°C. The reaction was monitored in real time in all
microchip elements with a fluorescence microscope equipped with a
Peltier element (12).
On-chip LDR.
For LDR, two interrogating oligonucleotide
probes were immobilized through their 5' ends in separate gel pads.
They were designed to discriminate between the wild-type gene with His
in position 526 (codon CAC; corresponding probe, 5'-CTA CCC GCT
GTC GTG GTT GAC CCA-3') and a mutant gene with the substitution
His-526-Leu (codon CTC; corresponding probe, 5'-CTA CCC GCT GTC
GTG GTT GAC CCT-3' ). The reaction mixture contained 20 mM
Tris-HCl (pH 8.3), 25 mM KCl, 10 mM MgCl2, 0.5 mM
NAD, 0.01% Triton X-100, 1 mg of acetylated bovine serum albumin
(Sigma)/ml, 40 to 240 nM single-stranded target DNA, 15 U of
thermostable Tth DNA-ligase (Ampligase; Epicentre Technologies, Madison, Wis.), and 600 to 720 nM detecting
oligonucleotide 5'-pCAA GCG CCG ACT GTA GGC ACT GGG-TR-3'.
The latter was phosphorylated on the 5' end and fluorescently labeled
with Texas Red on the 3' end.
The reaction chamber was incubated for 50 to 60 min at 40 to 42°C and
then was placed on a thermal table, and five to eight cycles were
carried out as follows: 10 s at 92°C, 16 min at 48 to 50°C.
The chamber was rinsed with several changes of 0.15 M NaCl for 5 min at
92°C. The reaction chamber was then disassembled and the chip was
rinsed with water and air dried, and its fluorescence was recorded.
Fluorescence measurement.
All measurements were taken in
real time using a setup of a fluorescence microscope equipped with a
CCD camera, a thermal table with step motors and movement controller,
and a computerized data acquisition system (12). Data
collection and processing were performed using dedicated software,
Special Hybridization Experiment Software, based on a LabVIEW interface
(National Instruments, Austin, Tex.).
Statistical analysis of the data.
The discriminating ability
of each pair of oligonucleotides immobilized on the MAGIChip was
assessed by the ratio r = Im/Ip, where
Im is the fluorescence of the gel pad
corresponding to an imperfect duplex and
Ip is the fluorescence of the gel pad
corresponding to a perfect duplex. Wild-type oligonucleotide probes
were always located in the upper row of the array. Therefore, for
wild-type target DNA, fluorescence of the upper gel pad in each column
equaled Ip. For mutant target DNA, on the
contrary, fluorescence of the gel pad corresponding to the mutation was
assumed to equal Ip, while fluorescence of
the corresponding wild-type gel pad equaled Im.
After a series of measurements, a median value (M) of all
r values was determined and the scattering of data
(L) was assessed as the following quartile deviation
(4):
where M1 is the median for all
values below M and M2 is
the median for all values above M.
 |
RESULTS |
Hybridization on TB-MAGIChip.
The method for identification of
Rifr mutants of M. tuberculosis by hybridization on a dedicated MAGIChip includes
three successive steps: (i) PCR amplification of clinical sample DNAs,
(ii) asymmetric PCR to yield a fluorescently labeled predominantly
single-stranded target DNA, and (iii) hybridization of the labeled
product to the chip with gel pads carrying immobilized
oligonucleotides. These oligonucleotides correspond to either the
wild-type or the mutant sequence. As they form, correspondingly, a
perfect or an imperfect match, the difference in these structures'
stability enables one to discriminate between positive and negative
hybridization signals by the intensity of fluorescence.
The TB-MAGIChip for identification of
Rifr strains of M. tuberculosis contains a call set of 42 oligonucleotides (Table
1). It can detect 30 of the most common
mutations in the rpoB gene responsible for the resistance.
Gel pads with immobilized oligonucleotides are arrayed in 12 columns
(Fig. 1), each column corresponding to a
single variable amino acid position. The upper gel pad in each column
(a1 through a12) matches the wild-type sequence, i.e., forms a perfect
duplex with the wild-type target DNA. Oligonucleotides immobilized in
the gel pads below form perfect duplexes with different mutant variants
of the same codon.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 1.
The images (A and B) and intensities (C and D) of
hybridization. The immobilized probes are listed in Table 1. (A and C)
Wild-type target DNA; (B and D) His-526-Tyr mutant target DNA.
The fluorescence intensities within each column were normalized to a
maximal fluorescence signal corresponding to a perfect hybridization
duplex. a. u., arbitrary units. The arrow in panel B points to the only
gel pad where a perfect duplex formed, resulting in a higher level of
fluorescence.
|
|
Figure 1A and C illustrate the hybridization of wild-type target DNA
with the TB-MAGIChip. The fluorescence of the gel pads in the upper row
is the brightest in each individual column. Only the oligonucleotides
in these pads form perfect duplexes with the target DNA.
A mutation in the RRDR segment of the rpoB gene results in
the formation of a perfect duplex and, therefore, bright fluorescence in a gel pad located in rows b through j. An example of hybridization of a mutant target DNA (His-526-Tyr) is shown in Fig. 1B and D. The
fluorescence of the gel pad j10 is much higher than the fluorescence of
a10, where the wild-type probe is immobilized, because this is the only
pad in the column where a perfect duplex has formed.
Optimization of hybridization on MAGIChip.
Melting
temperatures of perfect duplexes formed with oligonucleotides
immobilized on the TB-MAGIChip in 1 M NaCl are within the range of 58 to 63°C (Fig. 2A). To adapt
hybridization to be performed at 37°C, 1 M GuCNS (or 20% formamide)
was added to the hybridization buffer, which decreased the melting
temperature to about 47°C (Fig. 2A). However, the mechanical strength
of the gel pads incubated in the presence of GuCNS is higher than that in formamide.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 2.
Melting curves of hybridization duplexes. (A) Effect of
buffer composition on the melting temperature of a perfect duplex
formed between oligonucleotide probe a3 (Table 1) and a PCR-amplified
fragment of the wild-type rpoB gene (labeled target
DNA). The samples were melted in 1 M NaCl (curve 1), 1 M NaCl with 10%
formamide (curve 2), 20% formamide (curve 3), 30% formamide (curve
4), or 1 M GuCNS (curve 5). (B) Melting curves of perfect (curve 1) and
imperfect (curve 2) duplexes in 1 M GuCNS. The duplexes were
formed by a PCR-amplified fragment of the wild-type rpoB
gene and oligonucleotide probe a3 (perfect duplex) or b3 (imperfect
duplex). a. u., arbitrary units.
|
|
The difference in the intensity of fluorescence between perfect and
imperfect duplexes after hybridization reactions performed at different
temperatures (Fig. 2B) was determined. This parameter defines the
discrimination ability of the procedure, and it was at its highest
level when the hybridization was performed at 37°C. Therefore, the
optimal hybridization temperature in 1 M GuCNS was 37°C, 8 to 10°C
below the melting temperature, and partial equilibrium was achieved
after 14 h of incubation.
Every discriminating pair of oligonucleotides underwent control
hybridization with a previously characterized DNA sample carrying the
corresponding mutation. Some probes on the microchip corresponded to
the mutations that were not available in clinical samples. These probes
were successfully tested using synthetic DNA samples.
Analysis of mycobacterial DNA samples on TB-MAGIChip.
DNA
samples were isolated from 130 Rifr
strains of M. tuberculosis and hybridized with the
TB-MAGIChip. In 128 of them, mutations in the RRDR were identified. The
results of this experiment are summarized in Table
2. The results clearly demonstrate that
Ser-531 and His-526 amino acid substitutions are found most frequently, in agreement with the published data (for a review, see reference 20). Nineteen samples representing different mutations as
judged from their on-chip hybridization patterns were sequenced; the results of the sequencing fully confirmed the hybridization data. In
one of the samples that showed a wild-type pattern when hybridized with
the chip, no mutations in the RRDR were found by sequencing (see
Discussion).
Comparison between detection of RIF resistance in sputum by
hybridization with TB-MAGIChip and by conventional drug susceptibility
testing.
Thirty-one samples of sputum from patients with
clinically confirmed TB were each divided in two parts. One part was
used to prepare target DNA; the amplified DNA was then hybridized with the TB-MAGIChip. The other part was used to isolate and identify M. tuberculosis by using standard clinical methods and then
to determine its RIF resistance by the absolute concentration method.
The results of this experiment are summarized in Table
3. According to the hybridization
results, 20 samples were categorized as RIF susceptible, while 11 contained mutations (Ser-531-Leu, 8 samples; Asp-516-Val, 2 samples;
His-526-Arg, 1 sample).
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Comparison of RIF susceptibilities of M. tuberculosis in sputum specimens as assessed by on-chip
hybridization and conventional drug susceptibility testing
|
|
Statistical evaluation of the hybridization results.
The
discrimination ability of the TB-MAGIChip was assessed by the
r value (see Materials and Methods) for 18 pairs of
wild-type and mutant oligonucleotide probes. In six independent
series of experiments, hybridization was carried out with
wild-type DNA and DNA from five different mutants:
His-526-Tyr (CAC
TAC); Ser-522-Leu (TCG
TTG);
Leu-533-Pro (CTG
CCC); His-526-Asn (CAC
AAC); and double mutant Leu-511-Arg (CTG
CGG) and Asp-516-Tyr (GAC
TAC).
Each hybridization was performed eight times. Data for each individual
pair were then grouped together, and median values and quartile
deviations were determined (Table 4).
Identification of Rifr mutants by on-chip
PCR.
The on-chip PCR approach is a modification of allele-specific
PCR that had been considered as a tool for the detection of point
mutations (30). The sequences of allele-specific
immobilized primers and corresponding nucleotide and amino acid
substitutions are listed in Table 5.
During the first cycles, asymmetric PCR occurs in the liquid covering
the chip and results in a single-stranded product with a fluorescently
labeled primer at its 5' end. Accumulation of this product leads to its
hybridization to specific primers immobilized inside the gel pads and
their extension. Long perfect duplexes formed during this process have
significantly higher melting temperatures than do the short duplexes
between the single-stranded PCR product and immobilized primers.
Therefore, when the temperature exceeds that of primer annealing,
fluorescence can be observed only in those gel pads in which the
immobilized primer has been extended. Similar to the setup described
for hybridization experiments, the interrogating sets for individual
codons of RRDR were placed in columns with wild-type primers on top.
For wild-type target DNA, the upper gel pads must be the brightest; for
mutant samples, the most intense fluorescence was seen in one of the
pads described below. An example of on-chip PCR with DNA from wild-type
M. tuberculosis DNA and from the His-526-Asp (CAC
GAC)
mutant is shown in Fig. 3. In further
experiments, we tested DNA from 30 different mutant strains of M. tuberculosis, and the results were fully concordant with the
hybridization analysis of the same samples.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 3.
Allele-specific on-chip PCR. A strong fluorescence
signal is observed when the 3' nucleotide of the immobilized primer is
complementary to target DNA, extended by Taq polymerase,
and forms a stable duplex with the fluorescently labeled target DNA.
Immobilized primers are listed in Table 5. (A) Wild-type target DNA;
(B) His-526-Asp mutant target DNA (CAC GAC); the corresponding
gel pad is marked with an arrow.
|
|
Identification of Rifr mutants by on-chip
LDR.
To test the LDR-based approach to identify
Rifr mutations, a chip was designed with
two interrogating immobilized oligonucleotides. They discriminated
between a wild-type sequence encoding His-526 (codon CAC) and a mutant
sequence encoding Leu (codon CTC). The interrogating oligonucleotides
had T or A in the 3' position, resepectively. The reaction mixture
contained the detecting oligonucleotide which hybridized with the
target DNA immediately adjacent to the immobilized oligonucleotides and
carried 5' phosphate to make the ligation reaction possible and
3'-fluorescent label for detection. When the target DNA formed a
perfect hybridization duplex with the immobilized interrogating
nucleotide, the ligase covalently linked its 3'-terminal base to the
5'-terminal base of the detecting oligonucleotide which became an
integral part of the immobilized oligonucleotide. To enhance the
positive fluorescence signal, the reaction was carried out at
elevated temperature and all participating compounds underwent
multiple cycles of annealing, ligation, and melting. Therefore,
thermostable ligase has been used.
The results of on-chip LDR are shown in Fig.
4. The gel pads on the right contained
the oligonucleotide corresponding to the wild-type sequence, and those
on the left contained the oligonucleotide corresponding to the mutant
sequence. Using either wild-type or mutant DNA, the signal accumulated
almost exclusively in the corresponding pads (rows a and e). When the
samples were mixed in different proportions, various levels of
fluorescence were detected in both gel pads. In particular, there was a
definite signal in the left (mutant) gel pad when mutant DNA made up
just 1% of the total target DNA (row b). In control experiments,
neither variations in the amount of oligonucleotides immobilized in the
gel pads nor changes in the concentration of detecting oligonucleotide and target DNA resulted in false-positive or -negative signals (not
shown).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 4.
Detection of mutant DNA by on-chip LDR. Each reaction
mixture contained a total of 3 pmol of single-stranded DNA. Reaction a
was performed with wild-type DNA; reaction e was performed with
His-526-Leu mutant DNA; other reactions contained 3 pmol of wild-type
DNA with a mixture of 1% (b), 2% (c), or 10% (d) of the mutant
DNA.
|
|
 |
DISCUSSION |
Molecular analysis of M. tuberculosis is a promising
alternative to bacteriological assays. Using the state-of-the-art
technology of oligonucleotide microchips, we developed three approaches
to the detection of M. tuberculosis resistance to RIF in
both cultures and clinical samples: hybridization, on-chip PCR, and
on-chip LDR on dedicated TB-MAGIChips.
The use of the MAGIChip offers several advantages for RIF resistance
testing over alternative microchip technologies (34), e.g., GeneChips developed by Affymetrix, Inc. (Santa Clara, Calif.), and manufactured by solid-phase chemical synthesis of
oligonucleotides with photolithographic fabrication techniques. The
MAGIChips are lower in cost, simpler to use, and more efficient
in discrimination of the perfect and mismatched duplexes
(12). Because of the better discrimination capacity, the
analysis of specific sequences can be performed using a very limited
call set of oligonucleotides necessary and sufficient for
identification of known mutations. The latter consideration
dramatically decreases the cost of chip manufacturing and eliminates
the need for cumbersome mathematical interpretation of the results.
Furthermore, the readout of the results may be carried out not only by
using the fluorescence microscope setup described earlier (12) but also by a simplified version of the chip analyzer
developed in our laboratory (2). The latter device can be
equipped with either a CCD camera or a Polaroid camera and costs under
$2,000. In particular, the use of a Polaroid camera enables one to
analyze the results visually without any computations.
Finally, three-dimensional polyacrylamide gel pads offer much higher
capacity and therefore a stronger fluorescence signal than the
two-dimensional glass surface. Although there are certain steric
hindrances that limit even distribution of the reacting molecules
throughout the gel pads and result in higher intensity of the
fluorescence at their periphery, this does not affect signal discrimination. Presently we are investigating ways to increase the
porosity of the gel in order to make it more accessible for various
components of chemical reactions, particularly larger DNA molecules.
Optimization of hybridization on TB-MAGIChip for clinical
laboratories.
The conditions were optimized to perform
hybridization at 37°C (Fig. 2), which is convenient for clinical laboratories.
Initially, we found that the absolute fluorescence intensities in
individual gel pads of the TB-MAGIChip varied widely, and this made
visual interpretation of the results rather difficult. We attempted to
equalize the intensity of positive signals by adjusting the length of
the probes. However, for some probes this still did not help.
Apparently, under nonequilibrium conditions the formation of secondary
structures by both target DNA and immobilized oligonucleotides affects
the yield of annealed duplexes and therefore the intensity of the
corresponding fluorescence signals.
Sensitivity and specificity of hybridization and on-chip PCR.
In our experiments with Rifr strains,
128 out of 130 samples were mutant as judged by hybridization with the
TB-MAGIChip; therefore, in a real clinical situation they would be
correctly classified as resistant. Hence, the accuracy of the
hybridization protocol was better than 98%. Sequencing of the RRDR
from one of the Rifr samples that gave a
wild-type hybridization pattern on the TB-MAGIChip confirmed the
absence of any mutations. This is not surprising, since in about 4% of
all Rifr M. tuberculosis
strains the resistance is not determined by mutations in RRDR
(20).
In primary specimens, the detection of RIF susceptibility by
hybridization with the MAGIChip showed good correlation with bacteriological testing obtained by the absolute concentration method
(accuracy was better than 93%). The limited number of tested specimens
(31 altogether) calls for cautious interpretation of the results.
Nevertheless, the specificity of the procedure (i.e., the ability to
detect true susceptibility) was 100% and the sensitivity of the
procedure (i.e., the ability to detect true resistance) was reasonably
high (85%). The positive predictive value of a resistant result was
100%, while the negative predictive value was 90%.
These data indicate that hybridization with the TB-MAGIChip could be a
promising approach to fast detection of RIF sensitivity of TB pathogens
directly in clinical samples. The analysis takes less than 24 h
and is much faster than the most advanced bacteriological methods.
False-negative results obtained by hybridization with the TB-MAGIChip
may be caused by several factors: low content of
Rifr mycobacteria in the primary
population, resistance independent of mutations in RRDR, and rare
mutations that do not have complementary probes in the standard call
set on the chip. Despite all these drawbacks, the high positive
predictive value of the hybridization results enables physicians to
exclude RIF from the treatment regimen and seek an alternative drug.
There was full concordance between the analysis by hybridization on
TB-MAGIChip and on-chip PCR; in addition, the latter protocol can be
carried out in just 1.5 to 2 h.
Reproducibility of hybridization results.
For statistical
purposes, the r values were averaged using the median, which
is less sensitive to random deviations than other averages
(4). One of the reasons for observed experimental deviations could be minor differences in the process of chip
manufacturing. Even for mutations with the most significant scattering
of data (substitutions Gln-510-His and Leu-511-Pro), the quartile
deviation was well within the limit of confidence (Table 4), i.e., it
allowed for reliable discrimination between positive and negative
signals. Indeed, positive signals in these cases were still 2.5 and 3 times stronger than negative signals, respectively. This is sufficient to identify mutations visually without any special equipment. In other
words, in no case did chip-to-chip or probe-to-probe variations result
in the inversion of positive and negative readings, regardless of the
observed scattering of data and fluctuations of fluorescence intensity
for individual oligonucleotide probes.
On-chip LDR.
The method of on-chip LDR is especially
attractive for simultaneously identifying several variants of the
rpoB gene against a high background of the wild-type gene.
We succeeded in detecting a variant gene that made up only 1% of the
target sample. It has to be noted that this level of sensitivity has
been chosen as an arbitrary threshold for the bacteriological
definition of RIF sensitivity (37).
Several advantages offered by TB-MAGIChips and their potentially low
cost make them attractive enough for large-scale commercial production.
The on-chip PCR technique can also be extended to analysis of genes
responsible for resistance to other drugs for which genetic
determinants of resistance are known. One such method was described
recently (33). It enables one to simultaneously analyze
several mutations in three different genes responsible for resistance
to RIF, isoniazid, and streptomycin.
 |
ACKNOWLEDGMENTS |
This work was supported by the Moscow Government (a262), by grant
no. 5/2000 from the Russian Human Genome Program, and by the U.S.
Department of Energy at the initial stage of research.
We are grateful to V. Chupeeva and E. Kreindlin for the manufacturing
of microchips, to I. Taran, S. Surzhikov, and B. Chernov for the
synthesis of oligonucleotides, to E. Vishnevskaja and S. Tatkov for
bacterial DNA samples, and to V. Barsky for kindly providing the
portable chip analyzer prior to publication of the manuscript. The
assistance of Health Front Line, Ltd. (Champaign, Ill.), in the
preparation of the manuscript is appreciated.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Biochip
Technology Center, Engelhardt Institute of Molecular Biology, 32 Vavilova St., Moscow 119991, GSP-1, Russia. Phone: 7 (095) 135 0559. Fax: 7 (095) 135 1405. E-mail:
amir{at}genome.eimb.relarn.ru.
 |
REFERENCES |
| 1.
|
Badak, F. Z.,
D. L. Kiska,
S. Setterquist,
C. Hartley,
M. A. O'Connell, and R. L. Hopfer.
1996.
Comparison of mycobacteria growth indicator tube with BACTEC 460 for detection and recovery of mycobacteria from clinical specimens.
J. Clin. Microbiol.
34:2236-2239[Abstract].
|
| 2.
|
Bavykin, S. G.,
J. P. Akowski,
V. M. Zakhariev,
V. E. Barsky,
A. N. Perov, and A. D. Mirzabekov.
2001.
Portable system for microbial sample preparation and oligonucleotide microarray analysis.
Appl. Environ. Microbiol.
67:922-928[Abstract/Free Full Text].
|
| 3.
|
Benjamin, W. H., Jr.,
K. B. Waites,
A. Beverly,
L. Gibbs,
M. Waller,
S. Nix,
S. A. Moser, and M. Willert.
1998.
Comparison of MB/BacT system with a revised antibiotic supplement kit to the BACTEC 460 system for detection of mycobacteria in clinical specimens.
J. Clin. Microbiol.
36:3234-3238[Abstract/Free Full Text].
|
| 4.
|
Bocharov, P. P.
1994.
Series criterion based on median, p. 164.
In
A. B. Pechinkin (ed.), Mathematical statistics.RUDN, Moscow, Russia.
|
| 5.
|
Brunello, F., and R. Fontana.
2000.
Reliability of the MB/BacT system for testing susceptibility of Mycobacterium tuberculosis complex isolates to antituberculosis drugs.
J. Clin. Microbiol.
38:872-873[Abstract/Free Full Text].
|
| 6.
|
Cohn, D. L.,
F. Bustreo, and M. C. Raviglione.
1997.
Drug-resistant tuberculosis: review of the worldwide situation and the W. H. O./IUATLD global surveillance project.
Clin. Infect. Dis.
24:S121-S130.
|
| 7.
|
Coninx, R.,
G. E. Pfyffer,
C. Mathieu,
D. Savina,
M. Debacker,
F. Jafarov,
I. Jabrailov,
A. Ismailov,
F. Mirzoev,
R. de Haller, and F. Portaels.
1998.
Drug resistant tuberculosis in prisons in Azerbaijan: case study.
Br. Med. J.
316:1423-1425[Abstract/Free Full Text].
|
| 8.
|
De Beenhouwer, H.,
Z. Lhiang,
G. Jannes,
W. Mijs,
L. Machtelinckx,
R. Rossau,
H. Traore, and F. Portaels.
1995.
Rapid detection of rifampin resistance in sputum and biopsy specimens from tuberculosis patients by P. C. R. and line probe assay.
Tuber. Lung Dis.
76:425-430[CrossRef][Medline].
|
| 9.
|
Drobniewski, F. A.,
B. Watt,
E. G. Smith,
J. G. Magee,
R. Williams,
J. Holder, and J. Ostrowski.
1999.
A national audit of the laboratory diagnosis of tuberculosis and other mycobacterial diseases within the United Kingdom.
J. Clin. Pathol.
52:334-337[Abstract].
|
| 10.
|
Farmer, P. E.,
A. S. Kononets,
S. E. Borisov,
A. Goldfarb,
T. Healing, and M. McKee.
1999.
Recrudescent tuberculosis in the Russian Federation, p. 41-83.
In
The global impact of drug resistant tuberculosis.Program in Infectious Disease and Social Change. Harvard Medical School, Boston, Mass.
|
| 11.
|
Felmlee, T. A.,
Q. Lin, and A. C. Whelen.
1995.
Genomic detection of Mycobacterium tuberculosis rifampin resistance: comparison of single-strand conformation polymorphism and dideoxy fingerprinting.
J. Clin. Microbiol.
33:1617-1623[Abstract].
|
| 12.
|
Fotin, A.,
A. Drobyshev,
D. Proudnikov,
A. Perov, and A. Mirzabekov.
1998.
Parallel thermodynamic analysis of duplexes on oligodeoxyribonucleotide microchips.
Nucleic Acids Res.
26:1515-1521[Abstract/Free Full Text].
|
| 13.
|
Gingeras, T. R.,
G. Ghandour,
E. Wang,
A. Berno,
P. M. Small,
F. Drobniewski,
D. Alland,
E. Desmond,
M. Holodniy, and J. Drenkow.
1998.
Simultaneous genotyping and species identification using hybridization pattern recognition analysis of generic Mycobacterium DNA arrays.
Genome Res.
8:435-448[Abstract/Free Full Text].
|
| 14.
|
Heifets, L. B.
1991.
Drug susceptibility tests in the management of chemotherapy of tuberculosis, p. 90-121.
In
L. B. Heifets (ed.), Drug susceptibility of mycobacterial infections. CRC Press, Boca Raton, Fla.
|
| 15.
|
Hirano, K.,
C. Abe, and M. Takahashi.
1999.
Mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by line probe assay.
J. Clin. Microbiol.
37:2663-2666[Abstract/Free Full Text].
|
| 16.
|
Kapur, V.,
L. Li,
S. Iordanescu,
M. R. Hamrick,
A. Wanger,
B. N. Kreiswirth, and J. M. Musser.
1994.
Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase B subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas.
J. Clin. Microbiol.
32:1095-1098[Abstract/Free Full Text].
|
| 17.
|
Kent, P. T., and G. P. Kubica.
1985.
Public health mycobacteriology. A guide for the level III laboratory. U. S.
Department of Health and Human Services. Centers for Disease Control and Prevention, Atlanta, Ga.
|
| 18.
|
Metchok, B.,
F. S. Nolte, and R. J. Wallace, Jr.
1999.
Mycobacterium, p. 399-437.
In
P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.
|
| 19.
|
Moore, M.,
I. M. Onorato,
E. McCray, and K. G. Castro.
1997.
Trends in drug-resistant tuberculosis in the United States, 1993-1996.
JAMA
278:833-837[Abstract].
|
| 20.
|
Musser, J. M.
1995.
Antimicrobial agent resistance in mycobacteria: molecular genetic insights.
Clin. Microbiol. Rev.
8:496-514[Abstract].
|
| 21.
|
Nash, K. A.,
A. Gaytan, and C. B. Inderlied.
1997.
Detection of rifampin resistance in Mycobacterium tuberculosis by means of a rapid, simple, and specific RNA/RNA mismatch assay.
J. Infect. Dis.
176:533-536[Medline].
|
| 22.
|
Pfyffer, G. E.,
C. Cieslak,
H.-M. Welscher,
P. Kissling, and S. Ruesch-Gerdes.
1997.
Rapid detection of Mycobacteria in clinical specimens by using the automated BACTEC 9000 MB system and comparison with radiometric and solid-culture systems.
J. Clin. Microbiol.
35:2229-2234[Abstract].
|
| 23.
|
Rastogi, N.,
K. S. Goh, and H. L. David.
1989.
Drug susceptibility testing in tuberculosis: a comparison of the proportion method using Löwenstein-Jensen, Middlebrook 7H10 and 7H11 agar media and a radiometric method.
Res. Microbiol.
140:405-417[Medline].
|
| 24.
|
Raviglione, M. C.,
D. E. Snider, and A. Kochi.
1995.
Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic.
JAMA
273:220-226[Abstract].
|
| 25.
|
Rossau, R.,
H. Traore,
H. de Beenhouwer,
W. Mijs,
G. Jannes,
P. de Rijk, and F. Portaels.
1997.
Evaluation of the INNO-LIPA Rif TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin.
Antimicrob. Agents Chemother.
41:2093-2098[Abstract].
|
| 26.
|
Rüsch-Gerdes, S.,
C. Domehl,
G. Nardi,
M. R. Gismondo,
H.-M. Welscher, and G. E. Pfyffer.
1999.
Multicenter evaluation of the mycobacteria growth indicator tube for testing susceptibility of Mycobacterium tuberculosis to first-line drugs.
J. Clin. Microbiol.
37:45-48[Abstract/Free Full Text].
|
| 27.
|
Siddiqi, S. H.,
J. E. Hawkins, and A. Laszlo.
1985.
Interlaboratory drug susceptibility testing of Mycobacterium tuberculosis by radiometric procedure and two conventional methods.
J. Clin. Microbiol.
22:919-923[Abstract/Free Full Text].
|
| 28.
|
Sreevatsan, S.,
J. B. Bookout,
F. M. Ringpis,
S. L. Mogazeh,
B. N. Kreiswirth,
R. R. Pottathil, and R. R. Barathur.
1998.
Comparative evaluation of cleavase fragment length polymorphism with PCR-SSCP and PCR-RFLP to detect antimicrobial agent resistance in Mycobacterium tuberculosis.
Mol. Diagn.
3:81-91[CrossRef][Medline].
|
| 29.
|
Stepanshina, V. N.,
E. A. Panfertsev,
O. V. Korobova,
I. G. Shemyakin,
Y. G. Stepanshin,
I. M. Medvedeva, and I. R. Dorozhkova.
1999.
Drug-resistant strains of Mycobacterium tuberculosis isolated in Russia.
Int. J. Tuberc. Lung Dis.
3:149-152[Medline].
|
| 30.
|
Strizhkov, B. N.,
A. L. Drobyshev,
V. M. Mikhailovich, and A. D. Mirzabekov.
2000.
PCR amplification on a microarray of gel-immobilized oligonucleotides: detection of bacterial toxin- and drug-resistant genes and their mutations.
BioTechniques
29:844-854[Medline].
|
| 31.
|
Telenti, A.,
P. Imboden,
F. Marchesi,
D. Lowrie,
S. Cole,
M. J. Colston,
L. Matter,
K. Schopfer, and T. Bodmer.
1993.
Detection of rifampin-resistance mutations in Mycobacterium tuberculosis.
Lancet
341:647-650[CrossRef][Medline].
|
| 32.
|
Tenover, F. C.,
J. T. Crawford,
R. E. Huebner,
L. J. Geiter,
C. R. Horsburgh, Jr., and R. C. Good.
1993.
The resurgence of tuberculosis: is your laboratory ready?
J. Clin. Microbiol.
31:767-770[Free Full Text].
|
| 33.
| Tillib, S., B. Strizhkov, and A. Mirzabekov.
Integration of multiple PCR amplifications and DNA mutation analysis by
using oligonucleotide microchip. Anal. Biochem., in press.
|
| 34.
|
Troesch, A.,
H. Nguyen,
C. G. Miyada,
S. Desvarenne,
T. R. Gingeras,
P. M. Kaplan,
P. Cross, and C. Mabilat.
1999.
Mycobacterium species identification and rifampin resistance testing with high-density DNA probe arrays.
J. Clin. Microbiol.
37:49-55[Abstract/Free Full Text].
|
| 35.
| Victor, T. C., A. M. Jordaan, A. van G. Rie,
D. van der Spuy, M. Richardson, P. D. van Helden, and R. Warren. 1999. Detection of mutations in drug resistance genes of
Mycobacterium tuberculosis by a dot-blot hybridization
strategy. Tuber. Lung Dis. 79:343-348.
|
| 36.
|
Williams, D. L.,
C. Waguespack,
K. Eisenach,
J. T. Crawford,
F. Portaels,
M. Salfinger,
C. M. Nolan,
C. Abe,
V. Sticht-Groh, and T. P. Gillis.
1994.
Characterization of rifampin resistance in pathogenic mycobacteria.
Antimicrob. Agents Chemother.
38:2380-2386[Abstract/Free Full Text].
|
| 37.
|
World Health Organization/IUATLD Global Working Group on Tuberculosis Drug Resistance Surveillance.
1997.
Guidelines for surveillance of drug resistance in tuberculosis. World Health Organization publication WHO/TB/96.216.
World Health Organization, Geneva, Switzerland.
|
| 38.
|
Yershov, G.,
V. Barsky,
A. Belgovskiy,
E. Kirillov,
E. Kreindlin,
I. Ivanov,
S. Parinov,
D. Guschin,
A. Drobyshev,
S. Dubiley, and A. Mirzabekov.
1996.
DNA analysis and diagnostics on oligonucleotide microchips.
Proc. Natl. Acad. Sci. USA
93:4913-4918[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, July 2001, p. 2531-2540, Vol. 39, No. 7
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.7.2531-2540.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Afanas'ev, M. V., Ikryannikova, L. N., Il'ina, E. N., Sidorenko, S. V., Kuz'min, A. V., Larionova, E. E., Smirnova, T. G., Chernousova, L. N., Kamaev, E. Yu., Skorniakov, S. N., Kinsht, V. N., Cherednichenko, A. G., Govorun, V. M.
(2007). Molecular characteristics of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis isolates from the Russian Federation. J Antimicrob Chemother
59: 1057-1064
[Abstract]
[Full Text]
-
Ma, M., Wang, H., Yu, Y., Zhang, D., Liu, S.
(2007). Detection of antimicrobial resistance genes of pathogenic Salmonella from swine with DNA microarray. jvdi
19: 161-167
[Abstract]
[Full Text]
-
Caoili, J. C., Mayorova, A., Sikes, D., Hickman, L., Plikaytis, B. B., Shinnick, T. M.
(2006). Evaluation of the TB-Biochip Oligonucleotide Microarray System for Rapid Detection of Rifampin Resistance in Mycobacterium tuberculosis.. J. Clin. Microbiol.
44: 2378-2381
[Abstract]
[Full Text]
-
Aragon, L. M., Navarro, F., Heiser, V., Garrigo, M., Espanol, M., Coll, P.
(2006). Rapid detection of specific gene mutations associated with isoniazid or rifampicin resistance in Mycobacterium tuberculosis clinical isolates using non-fluorescent low-density DNA microarrays. J Antimicrob Chemother
57: 825-831
[Abstract]
[Full Text]
-
Peytavi, R., Raymond, F. R., Gagne, D., Picard, F. J., Jia, G., Zoval, J., Madou, M., Boissinot, K., Boissinot, M., Bissonnette, L., Ouellette, M., Bergeron, M. G.
(2005). Microfluidic Device for Rapid (<15 min) Automated Microarray Hybridization. Clin. Chem.
51: 1836-1844
[Abstract]
[Full Text]
-
Roudinskii, N. I., Sukhanova, A. L., Kazennova, E. V., Weber, J. N., Pokrovsky, V. V., Mikhailovich, V. M., Bobkov, A. F.
(2004). Diversity of Human Immunodeficiency Virus Type 1 Subtype A and CRF03_AB Protease in Eastern Europe: Selection of the V77I Variant and Its Rapid Spread in Injecting Drug User Populations. J. Virol.
78: 11276-11287
[Abstract]
[Full Text]
-
Deng, J.-Y., Zhang, X.-E., Lu, H.-B., Liu, Q., Zhang, Z.-P., Zhou, Y.-F., Xie, W.-H., Fu, Z.-J.
(2004). Multiplex Detection of Mutations in Clinical Isolates of Rifampin-Resistant Mycobacterium tuberculosis by Short Oligonucleotide Ligation Assay on DNA Chips. J. Clin. Microbiol.
42: 4850-4852
[Abstract]
[Full Text]
-
Yu, X., Susa, M., Knabbe, C., Schmid, R. D., Bachmann, T. T.
(2004). Development and Validation of a Diagnostic DNA Microarray To Detect Quinolone-Resistant Escherichia coli among Clinical Isolates. J. Clin. Microbiol.
42: 4083-4091
[Abstract]
[Full Text]
-
Nasedkina, T. V., Zharinov, V. S., Isaeva, E. A., Mityaeva, O. N., Yurasov, R. N., Surzhikov, S. A., Turigin, A. Y., Rubina, A. Y., Karachunskii, A. I., Gartenhaus, R. B., Mirzabekov, A. D.
(2003). Clinical Screening of Gene Rearrangements in Childhood Leukemia by Using a Multiplex Polymerase Chain Reaction-Microarray Approach. Clin. Cancer Res.
9: 5620-5629
[Abstract]
[Full Text]
-
Lapa, S., Mikheev, M., Shchelkunov, S., Mikhailovich, V., Sobolev, A., Blinov, V., Babkin, I., Guskov, A., Sokunova, E., Zasedatelev, A., Sandakhchiev, L., Mirzabekov, A.
(2002). Species-Level Identification of Orthopoxviruses with an Oligonucleotide Microchip. J. Clin. Microbiol.
40: 753-757
[Abstract]
[Full Text]